Sparks commentary - Oryzon Genomics

Healthcare

Sparks - Oryzon Genomics

More on this equity
Oryzon (BME: ORY) fortifies its IP portfolio
Published by Arron Aatkar

Oryzon Genomics has received an ‘Intention to grant’ communication from the European Patent Office relating to a patent application for its lead CNS asset, vafidemstat, entitled ‘Methods of treating borderline personality disorder’. Once granted, it will provide protection in Europe until at least 2040, excluding any potential patent term extensions that may provide additional protection. This news is incremental to Oryzon’s announcements earlier this quarter of the receipt of similar communications covering Australia, Malaysia, Mexico and Japan, fortifying the robust patent portfolio for the candidate.

Management is preparing for an end-of-Phase II meeting with the FDA to discuss a potential global registrational Phase III programme in borderline personality disorder; an update is expected in Q424.

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free